PMI Buys Israeli Marijuana Company for $650 Million

BusinessPMI by Jacky Yin
Jul.19.2023
PMI Buys Israeli Marijuana Company for $650 Million
Philip Morris International (PMI) is in the process of acquiring an Israeli medical marijuana company Syqe Medical for up to $650 million. Syqe's main product is said to be a medical marijuana-measured dose inhaler for pain relief.

On July 18, Israeli media outlet Calcalistech reported that Philip Morris International (PMI) is in the process of acquiring Israeli medical marijuana company Syqe Medical for up to $650 million. Syqe's main product is a medical marijuana-measured dose inhaler for pain relief.

 

菲莫国际加码医用大麻市场? 或以6.5亿美元收购以色列大麻公司
Syqe product | calcalistech

 

Acquisition of all shares for USD $650 million

According to the report, PMI will first invest $120 million to support the Syqe inhaler's approval by the U.S. Food and Drug Administration (FDA). If approval is granted through clinical trials, PMI will go on to purchase all remaining shares of the Israeli company for $650 million.

 

The deal will be carried out through PMI's subsidiary Vectura, which specializes in the inhaler space. PMI had acquired Vectura for £1 billion in 2021 as part of its strategy to transition to smoke-free world.

 

It is public information that in 2016, PMI made a $20 million investment in Syqe.

 

A number of independent patented technologies

If the acquisition goes through, it will be one of the biggest deals in the Israeli med-tech sector in recent years; and if it reaches a valuation of $650 million, Syqe will become one of the top 10 cannabis companies in the world.

 

Founded in 2011 by Perry Davidson, who still serves as CEO, Syqe holds around 120 patents, and its main innovations are the use of the raw inflorescence of the cannabis plant rather than processed products, and the ability to accurately measure the dosage given to patients.

 

It's worth noting that total investment in the company to date is $80 million, with Davidson holding more than 10 percent of the shares.

 

Currently, more than 80% of medical marijuana consumers use smoking products such as cigarettes and e-cigarettes, leading to potential overdoses, and Syqe's inhaler provides relief without the need for an overdose, avoiding the "psychoactive effect".

 

FDA approval is a key milestone

In the past, these inhalers were marketed and distributed through the Israeli pharmaceutical company Teva. Recently, however, Syqe has chosen to market independently and has entered into partnership agreements with the Ministry of Defense and Meuhedet HMO.

 

Syqe's primary target market is outside of Israel, and its FDA approval is a key milestone. According to the report, PMI will play an important role in getting Syqe through FDA approval. If successful, Syqe will be the first company in the world to receive FDA approval for the use of raw cannabis inflorescences as medicine.

 

PMI is one of the world's largest cigarette manufacturers with a market capitalization of $154 billion. In recent years, PMI has launched a new tobacco transformation strategy, and today more than one-third of its revenue comes from smokeless products, including heated tobacco products like IQOS.

 

According to PMI, the medical marijuana market is worth $24 billion, growing at a 15% annual rate through 2030. The wellness market, which includes cannabis-based tranquilizers and sleep aids, is estimated to be worth an additional $4 billion, with an 8% growth rate.

 

Syqe's inhaler is currently available in Israel and Australia, which are relatively small markets. The Israeli market is estimated at only NIS 100 million (approximately USD $27.5 million) per year, serving approximately 50,000 medical marijuana patients.

 

Reference:

【1】Philip Morris acquiring Cannabis inhaler developer Syqe Medical for up to $650 million

*The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the original author and refrain from forwarding directly from here.

U.S. Expands Illicit Vape Enforcement as ATF Brings PACT Act Powers Into Trade Fraud Task Force
U.S. Expands Illicit Vape Enforcement as ATF Brings PACT Act Powers Into Trade Fraud Task Force
The U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives said on September 23 that it has joined the interagency Trade Fraud Task Force to strengthen enforcement against illegal, misdeclared and smuggled vape and tobacco products. ATF will bring its authority under the Prevent All Cigarette Trafficking Act into the task force, including registration, reporting, shipping and record-inspection requirements covering interstate sales of electronic nicotine delivery systems. ATF said the move will strengthen its ability to trace illicit products from U.S. points of entry through domestic trafficking and distribution networks.
News
Sep.28 by 2Firsts Perspectives
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24
Product | JT Launches Three Autumn-Limited Ploom Tobacco Sticks in Japan Across EVO, MEVIUS and CAMEL Brands
Product | JT Launches Three Autumn-Limited Ploom Tobacco Sticks in Japan Across EVO, MEVIUS and CAMEL Brands
Japan Tobacco Inc. (JT) launched three limited-edition autumn tobacco sticks for its Ploom heated tobacco devices in Japan on October 16, 2026, under the EVO, MEVIUS and CAMEL brands. All three are regular tobacco variants with seasonal packaging. Each pack contains 20 sticks, priced at ¥620, ¥590 and ¥570, respectively, including tax. The products are compatible with all Ploom devices and are sold in limited quantities exclusively through the CLUB JT online store while supplies last.
product
Oct.20
Product | KT&G Launches lil HYBRID 3.0 Misty Rosé Edition II in South Korea With Two Pink Finishes at 88,000 Won
Product | KT&G Launches lil HYBRID 3.0 Misty Rosé Edition II in South Korea With Two Pink Finishes at 88,000 Won
South Korean tobacco company KT&G launched the limited-edition lil HYBRID 3.0 Misty Rosé Edition II on September 30, 2026, following the original Misty Rosé Edition introduced in November 2025. The new release comes in two pink finishes, Bloom Rosé and Viva Rosé, each priced at 88,000 won. Both versions initially went on sale through the lil Store online shop and lil MINIMALIUM flagship stores. From October 7, Bloom Rosé became available at approximately 1,500 lil Station retail outlets nationwide. The release retains the existing lil HYBRID 3.0 hybrid heated tobacco platform, with changes focused on exterior design and distribution.
product
Oct.10
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
The European Commission has clarified to 2Firsts that its proposed cardiovascular health checks would assess smoking, vaping and the use of smokeless nicotine products as part of patients’ medical histories. The Commission also said Member States may organise additional checks within their healthcare systems. In the same response, it pointed to JRC research on e-cigarettes, heated tobacco products and nicotine pouches that has fed into the evaluation of EU tobacco legislation.
Nov.09
Special Report|RLX Technology Consolidates European Distribution Business for First Time: Q3 2026 Revenue Rises Nearly 70%, Gross Margin Falls to 23.3%
Special Report|RLX Technology Consolidates European Distribution Business for First Time: Q3 2026 Revenue Rises Nearly 70%, Gross Margin Falls to 23.3%
RLX Technology reported a 69.7% year-on-year increase in third-quarter 2026 revenue to RMB1.92 billion ($285.9 million), driven primarily by the consolidation of a newly acquired Western European distributor. International markets accounted for 86.5% of revenue. The acquisition followed RLX's RMB744 million purchase of controlling interests in UK vaping company Totally Wicked in 2025, expanding the group's directly controlled European retail and distribution operations. SEC filings also show that purchases from Shenzhen Smoore Technology Limited declined from 80% of RLX's total purchases in 2022 to 23% in 2025. Third-quarter gross margin fell to 23.3%, while GAAP operating income declined 57.7%.
Business
Nov.20